Nerve stent

By designing bioadhesive ends at both ends of the fiber bundle, the problem that collagen fiber stent materials cannot form continuous connections in spinal cord injury repair in the prior art is solved, and the tight connection with the nerve injury end is achieved, which significantly promotes nerve regeneration and Repair effect.

CN222091905UActive Publication Date: 2024-12-03DB WUDEREGEN BIOMEDICAL TECH (JIANG SU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202322362088.9
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2023-08-31
Publication Date
2024-12-03
Estimated Expiration
2033-08-31

AI Technical Summary

Technical Problem

In the repair of spinal cord injury, existing fiber stent materials such as collagen cannot form continuous connection with the spinal cord injury end due to non-fluidity and low adhesion properties, resulting in poor neural signal connection and low repair efficiency.

Method used

Design the bioadhesive ends at both ends of the fiber bundle, and use dopamine-modified materials such as amino-containing biopolymers, hydroxy-containing biopolymers and metal chloride salts to form efficient adhesion ends to closely connect with the nerve damage ends and promote nerve regeneration. .

Benefits of technology

Effectively connect the nerve damage end, significantly promote nerve regeneration and repair, and improve the effect of spinal cord injury repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN222091905U_ABST
    Figure CN222091905U_ABST
Patent Text Reader

Abstract

The utility model relates to a nerve stent. The nerve scaffold comprises a fiber bundle, the two ends of the fiber bundle are connected with adhesion ends respectively, the fiber bundle comprises a plurality of fiber strips which are longitudinally arranged in parallel, and the fiber strips comprise any one or a combination of at least two of collagen fiber strips, chitosan fiber strips or hyaluronic acid fiber strips. The novel nerve stent is ingeniously designed, the adhesion ends made of biological glue are designed at the two ends of the fiber bundle, the nerve injury ends can be effectively connected, and nerve repair is facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model belongs to the technical field of medical materials and relates to a nerve stent. Background Art

[0002] Spinal cord injury (SCI) causes permanent and irreversible sensory and motor dysfunction below the injury level. It is the most complex and challenging neurological disease in clinical treatment, and imposes a heavy burden on patients, their families, and society. Spinal cord injury involves not only initial tissue damage, but also destructive secondary damage. Existing studies have shown that inhibitory myelin fragments, accumulation of reactive astrocytes, microglia, and immune cells, glial and fibrotic scars, etc. in the lesion site after spinal cord injury form an unfavorable microenvironment that lacks induction of regeneration, neurotrophic protection, etc., which inhibits endogenous regeneration and repair of the central nervous system, further aggravating the degree of injury and affecting functional recovery. In addition, after spinal cord nerve injury, cavities are usually formed at the injury site, causing nerve cells to lose the extracellular matrix for support and adhesion. Therefore, selecting an exogenous scaffold to provide structural support and a favorable microenvironment for nerve regeneration is expected to enhance the effect of nerve injury repair and provide a new means for the treatment of spinal cord injury.

[0003] Tissue engineering plays an important role in the treatment of nerve injuries. Natural polymer materials such as collagen, chitosan, and hyaluronic acid are abundant in source and have many advantages, such as good biodegradability, high biocompatibility, low immunity and modifiability, and are widely used in tissue engineering. In addition, the properties of the material affect the development of cells and tissues. For example, studies have shown that collagen can regulate the axon regeneration of dorsal root ganglia. In particular, collagen fiber scaffold materials, due to the orderly arrangement of fibers, can guide the oriented growth of nerves, which is more conducive to the reconstruction of neural circuits. However, for spinal cord injury repair, existing fiber scaffold materials such as collagen are non-fluid and have low adhesion properties. They cannot form a continuous connection with the injured end of the spinal cord, resulting in gaps between the scaffold material and the host spinal cord tissue during transplantation treatment, which hinders the connection of nerve signals, and there are problems such as poor functional reconstruction and low repair efficiency.

[0004] In summary, the development of new neural scaffolds can significantly improve the repair effect and is of great significance in the field of neural repair. Utility Model Content

[0005] In view of the deficiencies of the prior art and actual needs, the utility model provides a nerve scaffold with adhesive ends designed at both ends of the fiber bundle. As a nerve scaffold, it can form a close connection with the damaged end of the host nerve and promote nerve regeneration.

[0006] In order to achieve the above purpose, the utility model adopts the following technical solutions:

[0007] In a first aspect, the utility model provides a neural stent, which includes a fiber bundle, wherein both ends of the fiber bundle are respectively connected with adhesive ends, and the fiber bundle includes a plurality of longitudinally parallel fiber strips, and the fiber strips include any one of collagen fiber strips, chitosan fiber strips or hyaluronic acid fiber strips, or a combination of at least two of them.

[0008] The utility model ingeniously designs a novel nerve stent, and designs adhesive ends made of biological glue at both ends of the fiber bundle, which can effectively connect the damaged ends of the nerves and are beneficial to nerve repair.

[0009] It can be understood that the fiber strips commonly used in the art for nerve repair are all suitable for the present utility model.

[0010] Preferably, both ends of the fiber bundle are inserted into the adhesive end; and the adhesive end comprises a bioglue adhesive end.

[0011] Preferably, the fiber strips include collagen fiber strips, chitosan fiber strips or hyaluronic acid fiber strips, etc.

[0012] It can be understood that all commonly used implantable biological glues in the art are applicable to the present utility model.

[0013] In a specific embodiment of the utility model, the bio-glue at the adhesive end of the bio-glue is a dopamine-modified amino-containing bio-polymer, a hydroxyl-containing bio-polymer, an aldehyde-containing hydroxyl-containing bio-polymer, a chloride metal salt and a solvent composite bio-glue (reference CN114425103A). The bio-glue contains dopamine-modified amino-containing bio-polymer, a hydroxyl-containing bio-polymer, an aldehyde-containing hydroxyl-containing bio-polymer, a chloride metal salt and a solvent, and the mass ratio of the dopamine-modified amino-containing bio-polymer, the hydroxyl-containing bio-polymer, the aldehyde-containing hydroxyl-containing bio-polymer, the chloride metal salt and the solvent is 1:1-8:1-8:2-12:20-50; the dopamine-modified amino-containing bio-polymer is grafted with a dopamine group.

[0014] The preparation method of the bio-glue comprises:

[0015] The amino-containing biopolymer is dissolved in trifluoroacetic acid to form an amino-containing biopolymer solution, and then dopamine hydrochloride is added to the amino-containing biopolymer solution to form a first mixed solution, and the pH value of the obtained first mixed solution is controlled to be 5.5-6.0, and the concentration of the trifluoroacetic acid is 0.5wt%; the amino-containing biopolymer is selected from any one or a combination of two or more of collagen, chitosan, and gelatin; NHS and EDC are dissolved in water to form NHS solution and EDC solution respectively, and the pH values ​​of the obtained NHS solution and EDC solution are controlled to be 5.5-6.0; then the NHS solution and the EDC solution are added to the first mixed solution in sequence to form a first mixed reaction system, and the reaction is carried out at 4-36°C for 5-20h, and then dialyzed in a 4-10mmol / L hydrochloric acid solution. The method comprises the steps of: treating the dopamine-modified amino-containing biopolymer for 3 to 4 days, and then freeze-drying the dopamine-modified amino-containing biopolymer; wherein the dialysis treatment is at least used to remove toxic small molecule reagents; sequentially adding hydroxyl-containing biopolymer, p-benzaldehyde, 2,2-dihydroxymethylpropionic acid, and dicyclohexylcarbodiimide into tetrahydrofuran to form a second mixed reaction system, and then reacting the second mixed reaction system at ℃ for 6 to 18 hours in a closed environment and a protective atmosphere, and then post-treating the system to obtain the aldehyde-containing hydroxyl-containing biopolymer; and uniformly mixing the dopamine-modified amino-containing biopolymer, the hydroxyl-containing biopolymer, and the aldehyde-containing hydroxyl-containing biopolymer, and then adding a metal chloride salt and mixing the mixture evenly with a solvent and incubating the mixture for 10 to 48 hours, wherein the incubation is at least used to form metal oxide particles to obtain the bio-glue.

[0016] Preferably, the diameter of the fiber bundle is 1 to 10 mm, including but not limited to 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm or 9 mm.

[0017] Preferably, the diameters of the collagen fiber strips, chitosan fiber strips and hyaluronic acid fiber strips are independently 10nm to 300μm, including but not limited to 12nm, 15nm, 50nm, 100nm, 200nm, 1000nm, 10μm, 20μm, 50μm, 80μm, 90μm, 250μm, 260μm, 280μm, 290μm, 295μm, 200μm, and the lengths of the collagen fiber strips, chitosan fiber strips and hyaluronic acid fiber strips are independently 2 to 100mm, including but not limited to 3mm, 4mm, 5mm, 6mm, 7mm, 8mm, 20mm, 50mm, 60mm, 80mm, 90mm, 92mm, 95mm, 96mm, 98mm or 99mm.

[0018] Preferably, the shape of the adhesive end includes a cylinder, a cuboid, a cube or a frustum.

[0019] Preferably, the diameter of the cylinder is 1.5 to 10.5 mm, including but not limited to 1.6, 1.7, 1.8, 2 mm, 3 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm or 10 mm, and the height is 0.5 to 3 mm, including but not limited to 0.6 mm, 0.8 mm, 1 mm, 1.2 mm, 1.5 mm, 1.8 mm, 2 mm, 2.6 mm, 2.8 mm or 2.9 mm.

[0020] Compared with the prior art, the utility model has the following beneficial effects:

[0021] The utility model ingeniously designs a novel nerve stent, and designs adhesive ends made of bioglue at both ends of the fiber bundle, which can effectively connect the damaged ends of the nerves, promote nerve regeneration, and facilitate nerve repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a schematic diagram of the structure of the neural stent described in Example 1 of the utility model, wherein 1 is the adhesion end and 2 is the collagen fiber bundle. DETAILED DESCRIPTION

[0023] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It is understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0024] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0025] In the specific embodiment of the present invention, collagen fiber strips are used as an example to prepare a neural scaffold.

[0026] Example 1

[0027] This embodiment provides a neural stent, the structural diagram of which is shown in FIG. Figure 1 As shown, the nerve scaffold comprises a collagen fiber bundle 2, and both ends of the collagen fiber bundle 2 (with a diameter of 2 mm and a length of 4 mm) are respectively inserted into an adhesion end 1 (cylindrical, with a diameter of 2.3 mm and a height of 0.5 mm).

[0028] The preparation method of the neural scaffold comprises:

[0029] 1. Preparation of collagen fiber bundles

[0030] 40 mg of pure collagen was dissolved in 1 mL of 1% acetic acid aqueous solution, and completely dissolved into a transparent solution under the action of an ultrasonic oscillator and a 37°C water bath to form a collagen solution, which was placed at 0-4°C for 24 hours. After centrifugation to remove bubbles, it was sucked into a 1 mL syringe (syringe size was 27G), and then extruded into a pre-cooled NaHCO3 aqueous solution containing 50% wt EDC: NHS (4:1), and solidified at 25°C for 30 minutes to obtain pure collagen hydrogel fibers; the collagen hydrogel obtained by crosslinking was immersed in double distilled water and washed 3 times to obtain collagen hydrogel fiber strips. Multiple longitudinally arranged fiber strips were placed in a fiber bundle mold (length 4.5 mm, diameter 2.2 mm) to form a collagen hydrogel fiber bundle, and finally freeze-dried to prepare a collagen fiber bundle.

[0031] 2. Preparation of adhesion end

[0032] Weigh 500 mg of collagen and dissolve it in 50 mL of 0.5 wt% trifluoroacetic acid. Stir at 25 °C for 2 h until it is completely dissolved to form a collagen solution. Then add 0.5 g of dopamine hydrochloride to the collagen solution and stir to dissolve it under closed conditions. At the same time, adjust the pH value of the mixed solution to 5.5 by dropping 1 mol / L sodium hydroxide solution. Then weigh 0.85 g of NHS and dissolve it in 15 mL of deionized water to form an NHS solution. At the same time, adjust the pH value of the mixed solution to 5.5 by dropping 1 mol / L sodium hydroxide solution. Similarly, weigh 1.15 g of EDC and dissolve it in 15 mL of deionized water. An EDC solution is formed, and a 10 wt % trifluoroacetic acid solution is added dropwise to adjust the pH value of the mixed solution to 5.5; the prepared NHS and EDC solutions are added to the mixed solution in sequence, with an addition interval of 15 minutes, and then the entire reaction system is placed in a closed environment and reacted at 25° C. for 20 hours. After 20 hours, the reaction solution is transferred to a dialysis bag, and then dialyzed in a 4 mM hydrochloric acid solution for 3 days, and the dialysate is replaced once a day. The purified solution is frozen at -80 degrees and freeze-dried using a freeze dryer to obtain dopamine-modified collagen;

[0033] Weigh 6.4g of starch and dissolve it in 100mL of dry tetrahydrofuran, stir it thoroughly at 25°C, add 1.5g of p-benzaldehyde to the starch solution after about 1h, stir and dissolve it under airtight and dark conditions, then add 0.08g of DMPA (2,2-dihydroxymethylpropionic acid), and similarly weigh 2g of DCC (dicyclohexylcarbodiimide) and add it to the above solution. After nitrogen is introduced, the entire reaction system is sealed and reacted at 25°C for 18h. After 18h, the reaction solution is transferred to a beaker, filtered and washed with anhydrous ether and distilled water three times each, and dried on a rotary evaporator to obtain a white powder, i.e., aldehyde-modified starch;

[0034] 40 mg of dopamine-modified collagen was dissolved in 1 mL of deionized water, and the dopamine-modified collagen was fully dissolved by ultrasonic oscillation to obtain a dopamine-modified collagen solution; 100 mg of aldehyde-modified starch and unmodified starch, 300 mg of calcium chloride were weighed in a 10 mL EP tube, 1 mL of 0.1 mol / L sodium bicarbonate solution was added to the tube, and the mixture was stirred rapidly until the starch was completely dissolved to obtain a viscous solution, and the solution was ultrasonically centrifuged to remove bubbles; finally, the dopamine-modified collagen solution and the viscous solution were quickly mixed and stirred to fully mix, and the obtained mixed solution was sealed and incubated in a refrigerator at 4°C for 48 hours to obtain biological glue, which was made into a cylindrical shape with a diameter of 2.3 mm and a height of 0.5 mm, which was the adhesion end;

[0035] 3. Preparation of neural scaffolds

[0036] The adhesive ends are respectively inserted into both ends of the collagen fiber bundle to obtain a nerve scaffold.

[0037] Example 2

[0038] This embodiment provides a nerve stent, which comprises a collagen fiber bundle, and the two ends of the collagen fiber bundle (with a diameter of 10 mm and a length of 100 mm) are respectively inserted into adhesion ends (cylindrical, with a diameter of 10.5 mm and a height of 3 mm).

[0039] The preparation method of the neural scaffold comprises:

[0040] 1. Preparation of collagen fiber bundles

[0041] Refer to Example 1.

[0042] 2. Preparation of adhesion end

[0043] Weigh 1000 mg of chitosan and dissolve it in 50 mL of 0.5 wt% trifluoroacetic acid, stir at 25 ° C for 2 h until it is completely dissolved to form a collagen solution, then add 0.5 g of dopamine hydrochloride to the chitosan solution, stir and dissolve under closed conditions, and adjust the pH value of the mixed solution to 5.5 by dropping 1 mol / L sodium hydroxide solution; then weigh 0.85 g of NHS and dissolve it in 15 mL of deionized water to form an NHS solution, and adjust the pH value of the mixed solution to 5.5 by dropping 1 mol / L sodium hydroxide solution, and similarly weigh 1.15 g of EDC and dissolve it in 15 mL of deionized water. An EDC solution is formed, and a 10 wt % trifluoroacetic acid solution is added dropwise to adjust the pH value of the mixed solution to 5.5; the prepared NHS and EDC solutions are added to the mixed solution in sequence, with an addition interval of 15 minutes, and then the entire reaction system is placed in a closed environment and reacted at 25° C. for 20 hours. After 20 hours, the reaction solution is transferred to a dialysis bag, and then dialyzed in an 8 mM hydrochloric acid solution for 3 days, and the dialysate is replaced once a day. The purified solution is frozen at -80° C. and freeze-dried using a freeze dryer to obtain dopamine-modified collagen;

[0044] Weigh 6.4g of starch and dissolve it in 100mL of dry tetrahydrofuran, stir it thoroughly at 25°C, add 1.5g of p-benzaldehyde to the starch solution after about 1h, stir and dissolve it under airtight and dark conditions, then add 0.08g of DMPA (2,2-dihydroxymethylpropionic acid), and similarly weigh 2g of DCC (dicyclohexylcarbodiimide) and add it to the above solution. After nitrogen is introduced, the entire reaction system is sealed and reacted at 25°C for 18h. After 18h, the reaction solution is transferred to a beaker, filtered and washed with anhydrous ether and distilled water three times each, and dried on a rotary evaporator to obtain a white powder, i.e., aldehyde-modified starch;

[0045] 80 mg of dopamine-modified collagen was dissolved in 1 mL of deionized water, and the dopamine-modified chitosan was fully dissolved by ultrasonic oscillation to obtain a dopamine-modified collagen solution; 100 mg of aldehyde-modified starch and unmodified starch, 300 mg of ferric chloride were weighed in a 10 mL EP tube, 1 mL of PBS solution was added to the tube, and it was quickly stirred until the starch was completely dissolved to obtain a viscous solution, and the solution was ultrasonically centrifuged to remove bubbles; finally, the dopamine-modified chitosan solution and the viscous solution were quickly mixed and stirred to make them fully mixed, and the obtained mixed solution was sealed and incubated in a refrigerator at 4°C for 48 hours to obtain biological glue, which was made into a cylindrical shape with a diameter of 10.5 mm and a height of 3 mm, which was the adhesion end;

[0046] 3. Preparation of neural scaffolds

[0047] The adhesive ends are respectively inserted into both ends of the collagen fiber bundle to obtain a nerve scaffold.

[0048] Example 3

[0049] This embodiment provides a nerve stent, which comprises a collagen fiber bundle, and both ends of the collagen fiber bundle (with a diameter of 1 mm and a length of 2 mm) are respectively inserted into adhesion ends (cylindrical, with a diameter of 1.2 mm and a height of 0.5 mm).

[0050] The preparation method of the neural scaffold is as described in Example 1.

[0051] Test Example 1

[0052] This test example uses the nerve scaffold prepared in Example 1 as an example to verify the nerve repair effect.

[0053] The experimental animals were female SD rats (4-6 weeks old, purchased from Shanghai Slake Experimental Animal Co., Ltd.), weighing 180-200 g. They were fasted and deprived of water one day before the experiment. 20 rats were randomly divided into 2 groups, a collagen fiber bundle group (control) and a nerve scaffold group.

[0054] Anesthesia: 10% chloral hydrate 0.5g / kg intraperitoneal injection, deep anesthesia, otherwise an additional 0.05g / kg.

[0055] Surgery: The rats were fixed in the prone position, the hair was moistened with alcohol, shaved, and then the exposed skin was wiped with iodine tincture for disinfection. A longitudinal incision was made on the surface of the T8 spinous process along the midline of the spinal cord, the T8 position was accurately found, the muscles on both sides were spread open with a spreader, and the cone plate was opened with a pointed needle holder to expose the spinal cord, and a 4mm transverse section was performed at the T8 segment with microscissors. Pressing with gelatin sponge to stop bleeding, then each group of materials was placed in the transverse section, the muscles and skin were sutured in turn, disinfected with iodine, injected with antibiotics and placed in a cage, and the rats were cared for on time after surgery. Two months after the rat SCI repair treatment, 2% sodium pentobarbital solution (0.15mL / 100g) was injected intraperitoneally for anesthesia, the chest was opened in the supine position, the heart was exposed, the apex of the heart was cannulated to the aorta, the right atrial appendage was cut open, PBS was rinsed until no blood flowed out, and 4% paraformaldehyde was replaced for continued fixation. The spinal cord was removed by cutting the vertebral column and fixed in 4% paraformaldehyde for 48 h. The spinal cord was immersed in 20% sucrose solution until the tissue sank to the bottom. The solution was then replaced with 30% sucrose solution and immersed in 12 μm thick tissue slices. The tissue was then cryo-embedded in OCT compound (Tissue-Tek) and cut into 12 μm thick tissue slices using a cryostat.

[0056] Take out the spinal cord tissue slices to be tested, wash them with PBS for 3 times, 5 min / time, wash off OTC, circle the area of ​​the material to be stained with a marker; add 4% paraformaldehyde solution to cover the slices, and fix at 25°C for 30 min; discard the 4% paraformaldehyde, wash with PBS for 3 times, 5 min / time; add 0.5% triton-X100, and punch at room temperature for 5 min (the concentration of triton-X100 can be between 0.3% and 0.5%); discard triton-X100, wash with PBS for 3 times, 5 min / time; discard PBS, add appropriate amount of 5% BSA to block at room temperature for 1 h; discard 5% BSA, add primary antibody marker (usually 1:500 dilution), incubate at 4℃ overnight (or room temperature for 2h); discard the primary antibody, wash 3 times with PBS, 5min / time (note, this step needs to clean the residual primary antibody); discard PBS, add secondary antibody (diluted according to the instructions) (1:1000 dilution), incubate at room temperature in the dark for 2h; aspirate and discard the secondary antibody, wash 3 times with PBS, 5min / time; add sealing agent (sealing agent comes with DAPI), cover with coverslip (process of staining cell nucleus); observe with laser confocal microscope, and perform statistical analysis to analyze the expression of MAP-2.

[0057] MAP-2 is an important marker for mature neurons. The statistical analysis results showed that the MAP-2 positive rate in the nerve scaffold group was 13.9±0.6%, while in the fiber bundle repair group only, the rate was only 8.9±0.4%. It can be seen that the MAP-2 positive rate in the nerve scaffold group was higher, indicating that the nerve scaffold with an adhesive end designed in the present invention can significantly promote nerve regeneration in the spinal cord injury area.

[0058] In summary, the utility model ingeniously designs a new type of nerve scaffold, and designs adhesive ends made of bioglue at both ends of the fiber bundle, which can form a close connection with the damaged end of the host nerve, promote nerve regeneration, and facilitate nerve repair.

[0059] The applicant declares that the utility model uses the above-mentioned embodiments to illustrate the detailed method of the utility model, but the utility model is not limited to the above-mentioned detailed method, that is, it does not mean that the utility model must rely on the above-mentioned detailed method to be implemented. The technicians in the relevant technical field should understand that any improvement of the utility model, the equivalent replacement of the raw materials of the utility model product, the addition of auxiliary components, the selection of specific methods, etc., all fall within the protection scope and disclosure scope of the utility model.

Claims

1. A neural stent, characterized in that: The neural stent comprises a fiber bundle, and both ends of the fiber bundle are respectively connected with biological glue adhesion ends; The fiber bundle comprises a plurality of collagen fiber strips arranged longitudinally and in parallel; The two ends of the fiber bundle are inserted into the bioadhesive end; The diameter of the fiber bundle is 1 to 10 mm; The diameter of the collagen fiber strips is 10nm to 300μm; The length of the collagen fiber strips is 2 to 100 mm; The shape of the bioadhesive end includes a cylinder, a cuboid, a cube or a frustum.

2. The neural stent according to claim 1, characterized in that: The diameter of the cylinder is 1.5 to 10.5 mm.

3. The neural stent according to claim 1, characterized in that: The height of the cylinder is 0.5-3 mm.